Latest AXGN news and sentiment

Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference

Axogen, Inc. (NASDAQ: AXGN) announced its participation in the 24th Annual Morgan Stanley Global Healthcare Conference. Management will be available for one-on-one investor meetings on Tuesday, September 15, 2026. Axogen specializes in developing and marketing surgical solutions for peripheral nerve function restoration.

Axogen stock hits 52-week high at 51.13 USD

Axogen Inc.'s stock reached a new 52-week high of $51.13, reflecting a remarkable 214.19% increase over the past year. Despite this growth and positive revenue figures, an InvestingPro tip suggests the stock might be overvalued. Analysts have raised price targets, highlighting the company's strong market position and growth prospects in the peripheral nerve repair market.

Axogen (AXGN) Q2 2026 Earnings Call Transcript

Axogen Inc (MEX:AXGN) Stock Price, Trades & News

Axogen Inc (MEX:AXGN) Stock Earnings Transcripts

Operating margin % of Axogen, Inc. – BMV:AXGN

The article focuses on the operating margin percentage of Axogen, Inc. (BMV:AXGN), a company listed on the Mexican Stock Exchange under the Health Technology sector. It appears to be a financial data page from TradingView, indicating that the market for this stock was closed with no trades. The core content highlights the company's operating margin, period value, and changes.

Price to sales ratio of Axogen, Inc. – BMV:AXGN

This page provides financial information for Axogen, Inc. (BMV:AXGN) on TradingView, specifically focusing on its Price to Sales ratio. It indicates that the market for AXGN is currently closed with no trades. The content also lists various features and services offered by TradingView.

Axogen, Inc. Cash Flow – BIVA:AXGN

Axogen, Inc. (BIVA:AXGN) reported its Q2 2026 free cash flow at 110.76 million MXN, a significant improvement from -52.88 million MXN in 2025. The company's operating cash flow for 2025 was 14.64 million MXN. The article provides a high-level overview of the company's cash flow activities for recent years.

Total assets of Axogen, Inc. – BMV:AXGN

This page from TradingView provides financial information for Axogen, Inc. (BMV:AXGN), specifically focusing on its total assets. The article indicates that the market was closed and no trades were made at the time of publication, and it highlights the availability of historical data for the company's assets.

AXGN Stock Price and Chart — BIVA:AXGN

This page provides a comprehensive overview of Axogen, Inc. (AXGN) stock, traded on BIVA. It includes key financial stats such as market capitalization, revenue, and EPS, along with company information and employee data. The article also features analyst ratings, investment ideas, and details on ETFs holding Axogen stock, offering a complete picture for potential investors.

Tocqueville Asset Management L.P. Takes $8.03 Million Position in AxoGen, Inc. $AXGN

Tocqueville Asset Management L.P. has acquired a new position in AxoGen, Inc. (NASDAQ:AXGN), purchasing 173,900 shares valued at approximately $8.03 million. Despite institutional investors owning over 80% of the company and a "Moderate Buy" consensus rating from analysts, AxoGen remains unprofitable, with insiders selling significant amounts of stock. The company recently reported quarterly revenue of $69.73 million and adjusted earnings of $0.12 per share, matching earnings expectations while exceeding revenue estimates.

Axogen stock reaches 52-week high at 50.0 USD

Axogen Inc. (AXGN) has reached a new 52-week high of $50.00, reflecting a 222.92% growth over the past year and strong market sentiment. Despite this achievement, InvestingPro analysis suggests the stock is overvalued. The company recently reported significant revenue growth of 23% in Q2 2026, surpassing analyst estimates, leading to increased price targets from H.C. Wainwright and Citizens.

First Light Asset Management (AXGN) discloses 7.58% Axogen stake for Mathew Arens

First Light Asset Management, LLC and Mathew P. Arens have filed an amended Schedule 13G disclosing their beneficial ownership in Axogen, Inc. First Light Asset Management may be deemed to beneficially own 3,746,380 shares (6.97% of the class), while Mathew P. Arens may be deemed to beneficially own 4,072,910 shares (7.58% of the class). Arens's ownership includes shares controlled through the Manager, direct holdings, and a joint account.

Axogen (AXGN) Q2 2026 Earnings Call Transcript

Axogen, Inc. SEC Filing (Aug 11, 2026)

This article reports on an SEC Form 144 filing by Axogen, Inc. (AXGN) on August 11, 2026, detailing a proposed sale of 13,353 common shares with an aggregate market value of $643,881.66 through Morgan Stanley Smith Barney LLC. The securities were acquired on the same date through the exercise of stock options. The filing indicates a neutral impact and sentiment according to AI analysis.

Axogen stock hits 52-week high at 47.09 USD By Investing.com

Axogen Inc. (AXGN) stock reached a new 52-week high of $47.09, trading at $47.11 with a market capitalization of $2.52 billion, representing a 231.91% surge over the past year. InvestingPro analysis indicates the stock is currently overvalued, yet net income is projected to grow, with analysts forecasting profitability. Recent Q2 2026 financial results showed revenue of $69.7 million, exceeding estimates, and analysts have raised price targets for the company.